- Home
- NWE vs NAMS Comparison
NWE vs NAMS Comparison
Compare NWE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWE
- NAMS
- Stock Information
- Founded
- NWE 1923
- NAMS 2019
- Country
- NWE United States
- NAMS Netherlands
- Employees
- NWE N/A
- NAMS N/A
- Industry
- NWE Power Generation
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- NWE Utilities
- NAMS Health Care
- Exchange
- NWE Nasdaq
- NAMS Nasdaq
- Market Cap
- NWE 3.3B
- NAMS 2.7B
- IPO Year
- NWE N/A
- NAMS N/A
- Fundamental
- Price
- NWE $54.40
- NAMS $23.55
- Analyst Decision
- NWE Buy
- NAMS Strong Buy
- Analyst Count
- NWE 7
- NAMS 7
- Target Price
- NWE $57.50
- NAMS $38.17
- AVG Volume (30 Days)
- NWE 387.5K
- NAMS 581.4K
- Earning Date
- NWE 02-12-2025
- NAMS 02-06-2025
- Dividend Yield
- NWE 4.78%
- NAMS N/A
- EPS Growth
- NWE 24.01
- NAMS N/A
- EPS
- NWE 3.70
- NAMS N/A
- Revenue
- NWE $1,496,441,000.00
- NAMS $33,594,000.00
- Revenue This Year
- NWE $9.20
- NAMS $131.53
- Revenue Next Year
- NWE $4.51
- NAMS N/A
- P/E Ratio
- NWE $14.71
- NAMS N/A
- Revenue Growth
- NWE 0.34
- NAMS 78.77
- 52 Week Low
- NWE $46.15
- NAMS $15.19
- 52 Week High
- NWE $57.49
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- NWE 58.65
- NAMS 44.17
- Support Level
- NWE $50.77
- NAMS $22.53
- Resistance Level
- NWE $52.50
- NAMS $26.71
- Average True Range (ATR)
- NWE 0.95
- NAMS 0.97
- MACD
- NWE 0.27
- NAMS -0.45
- Stochastic Oscillator
- NWE 90.30
- NAMS 23.89
About NWE NorthWestern Energy Group Inc.
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric utility operations, which include the generation, purchase, transmission, and distribution of electricity, and Natural Gas utility operations, which include the production, purchase, transmission, storage, and distribution of natural gas. The company uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of revenue from Electric utility operations segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.